The use of nicardipine for electroconvulsive therapy: A dose-ranging study

Yunan Zhang, Paul F. White, Larry Thornton, Lisa Perdue, Michael Downing

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A wide variety of vasoactive drugs have been used to treat the acute hypertensive response to electroconvulsive therapy (ECT). We designed this randomized, double-blind, saline-controlled, crossover study to compare three different doses of nicardipine when administered before the ECT stimulus. Twenty-five patients undergoing a series of 4 ECT treatments received bolus injections of either saline or nicardipine 20,40, or 80 μg/kg IV in a random sequence during a standardized methohexital (1 mg/kg) and succinylcholine (1 mg/kg) anesthetic technique. The mean arterial blood pressure (MAP) and heart rate values were recorded at specific time intervals, as were the duration of seizure activity and the need for rescue labetalol. Both the 40 and 80 μg/kg doses of nicardipine reduced the percentage increase in MAP above the baseline value compared with the saline group (7% and 7% versus 30%, respectively). Nicardipine 40 and 80 μg/kg were also associated with a significant reduction in the need for labetalol (7 ± 3 mg and 5 ± 0 mg versus 22 ± 10 mg in the saline group). Compared with the 40 μg/kg dose, nicardipine 80 μg/kg was associated with a more rapid heart rate at the time the ECT stimulus was applied. The 80 μg/kg dose was also associated with a reduced MAP value on awakening compared with the baseline value (91 ± 12 mm Hg versus 102 ± 8 mm Hg). We conclude that a bolus injection of nicardipine 40 μg/kg IV immediately before the ECT stimulus was optimal for controlling the acute hemodynamic response to ECT treatments.

Original languageEnglish (US)
Pages (from-to)378-381
Number of pages4
JournalAnesthesia and Analgesia
Volume100
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Nicardipine
Electroconvulsive Therapy
Arterial Pressure
Labetalol
Heart Rate
Methohexital
Injections
Succinylcholine
Cross-Over Studies
Anesthetics
Seizures
Hemodynamics
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

The use of nicardipine for electroconvulsive therapy : A dose-ranging study. / Zhang, Yunan; White, Paul F.; Thornton, Larry; Perdue, Lisa; Downing, Michael.

In: Anesthesia and Analgesia, Vol. 100, No. 2, 02.2005, p. 378-381.

Research output: Contribution to journalArticle

Zhang, Yunan ; White, Paul F. ; Thornton, Larry ; Perdue, Lisa ; Downing, Michael. / The use of nicardipine for electroconvulsive therapy : A dose-ranging study. In: Anesthesia and Analgesia. 2005 ; Vol. 100, No. 2. pp. 378-381.
@article{088d1cbb9a954ed9af52d73b0c81d466,
title = "The use of nicardipine for electroconvulsive therapy: A dose-ranging study",
abstract = "A wide variety of vasoactive drugs have been used to treat the acute hypertensive response to electroconvulsive therapy (ECT). We designed this randomized, double-blind, saline-controlled, crossover study to compare three different doses of nicardipine when administered before the ECT stimulus. Twenty-five patients undergoing a series of 4 ECT treatments received bolus injections of either saline or nicardipine 20,40, or 80 μg/kg IV in a random sequence during a standardized methohexital (1 mg/kg) and succinylcholine (1 mg/kg) anesthetic technique. The mean arterial blood pressure (MAP) and heart rate values were recorded at specific time intervals, as were the duration of seizure activity and the need for rescue labetalol. Both the 40 and 80 μg/kg doses of nicardipine reduced the percentage increase in MAP above the baseline value compared with the saline group (7{\%} and 7{\%} versus 30{\%}, respectively). Nicardipine 40 and 80 μg/kg were also associated with a significant reduction in the need for labetalol (7 ± 3 mg and 5 ± 0 mg versus 22 ± 10 mg in the saline group). Compared with the 40 μg/kg dose, nicardipine 80 μg/kg was associated with a more rapid heart rate at the time the ECT stimulus was applied. The 80 μg/kg dose was also associated with a reduced MAP value on awakening compared with the baseline value (91 ± 12 mm Hg versus 102 ± 8 mm Hg). We conclude that a bolus injection of nicardipine 40 μg/kg IV immediately before the ECT stimulus was optimal for controlling the acute hemodynamic response to ECT treatments.",
author = "Yunan Zhang and White, {Paul F.} and Larry Thornton and Lisa Perdue and Michael Downing",
year = "2005",
month = "2",
doi = "10.1213/01.ANE.0000144419.44481.59",
language = "English (US)",
volume = "100",
pages = "378--381",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The use of nicardipine for electroconvulsive therapy

T2 - A dose-ranging study

AU - Zhang, Yunan

AU - White, Paul F.

AU - Thornton, Larry

AU - Perdue, Lisa

AU - Downing, Michael

PY - 2005/2

Y1 - 2005/2

N2 - A wide variety of vasoactive drugs have been used to treat the acute hypertensive response to electroconvulsive therapy (ECT). We designed this randomized, double-blind, saline-controlled, crossover study to compare three different doses of nicardipine when administered before the ECT stimulus. Twenty-five patients undergoing a series of 4 ECT treatments received bolus injections of either saline or nicardipine 20,40, or 80 μg/kg IV in a random sequence during a standardized methohexital (1 mg/kg) and succinylcholine (1 mg/kg) anesthetic technique. The mean arterial blood pressure (MAP) and heart rate values were recorded at specific time intervals, as were the duration of seizure activity and the need for rescue labetalol. Both the 40 and 80 μg/kg doses of nicardipine reduced the percentage increase in MAP above the baseline value compared with the saline group (7% and 7% versus 30%, respectively). Nicardipine 40 and 80 μg/kg were also associated with a significant reduction in the need for labetalol (7 ± 3 mg and 5 ± 0 mg versus 22 ± 10 mg in the saline group). Compared with the 40 μg/kg dose, nicardipine 80 μg/kg was associated with a more rapid heart rate at the time the ECT stimulus was applied. The 80 μg/kg dose was also associated with a reduced MAP value on awakening compared with the baseline value (91 ± 12 mm Hg versus 102 ± 8 mm Hg). We conclude that a bolus injection of nicardipine 40 μg/kg IV immediately before the ECT stimulus was optimal for controlling the acute hemodynamic response to ECT treatments.

AB - A wide variety of vasoactive drugs have been used to treat the acute hypertensive response to electroconvulsive therapy (ECT). We designed this randomized, double-blind, saline-controlled, crossover study to compare three different doses of nicardipine when administered before the ECT stimulus. Twenty-five patients undergoing a series of 4 ECT treatments received bolus injections of either saline or nicardipine 20,40, or 80 μg/kg IV in a random sequence during a standardized methohexital (1 mg/kg) and succinylcholine (1 mg/kg) anesthetic technique. The mean arterial blood pressure (MAP) and heart rate values were recorded at specific time intervals, as were the duration of seizure activity and the need for rescue labetalol. Both the 40 and 80 μg/kg doses of nicardipine reduced the percentage increase in MAP above the baseline value compared with the saline group (7% and 7% versus 30%, respectively). Nicardipine 40 and 80 μg/kg were also associated with a significant reduction in the need for labetalol (7 ± 3 mg and 5 ± 0 mg versus 22 ± 10 mg in the saline group). Compared with the 40 μg/kg dose, nicardipine 80 μg/kg was associated with a more rapid heart rate at the time the ECT stimulus was applied. The 80 μg/kg dose was also associated with a reduced MAP value on awakening compared with the baseline value (91 ± 12 mm Hg versus 102 ± 8 mm Hg). We conclude that a bolus injection of nicardipine 40 μg/kg IV immediately before the ECT stimulus was optimal for controlling the acute hemodynamic response to ECT treatments.

UR - http://www.scopus.com/inward/record.url?scp=12844251300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844251300&partnerID=8YFLogxK

U2 - 10.1213/01.ANE.0000144419.44481.59

DO - 10.1213/01.ANE.0000144419.44481.59

M3 - Article

C2 - 15673861

AN - SCOPUS:12844251300

VL - 100

SP - 378

EP - 381

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 2

ER -